Description:
1. Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free
survival will be the primary outcome. Subjects will need to have Epidermal Growth Factor
Receptor (EGFR) wild-type, locally advance or metastatic NSCLC and have their cancer
progressed after at least one prior systemic anti-cancer therapy, available recent or
archival tumor specimen and may not have had previous EGFR-targeted regimen, anti-HER2
(Human Epidermal Growth Factor Receptor 2), anti-HER3, or anti-HER4 therapy. Subjects
may have high heregulin or low heregulin.
2. Part B: Subjects will receive Patritumab or placebo with erlotinib. Overall survival
will be the primary outcome. Subjects will need to have EGFR wild-type, locally advance
or metastatic NSCLC and have their cancer progressed after at least one prior systemic
anti-cancer therapy, available recent or archival tumor specimen and may not have had
previous EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy. Only
subjects with high heregulin will be enrolled.
Title
- Brief Title: Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
- Official Title: Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Clinical Trial IDs
- ORG STUDY ID:
U31287-A-U301
- SECONDARY ID:
2013-004371-12
- NCT ID:
NCT02134015
Conditions
- Lung Cancer
- Non-small Cell Lung Cancer
Interventions
Drug | Synonyms | Arms |
---|
Patritumab | U3-1287 | Patritumab + erlotinib |
Erlotinib | | Patritumab + erlotinib |
Placebo | Matching Placebo | Placebo + erlotinib |
Purpose
1. Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free
survival will be the primary outcome. Subjects will need to have Epidermal Growth Factor
Receptor (EGFR) wild-type, locally advance or metastatic NSCLC and have their cancer
progressed after at least one prior systemic anti-cancer therapy, available recent or
archival tumor specimen and may not have had previous EGFR-targeted regimen, anti-HER2
(Human Epidermal Growth Factor Receptor 2), anti-HER3, or anti-HER4 therapy. Subjects
may have high heregulin or low heregulin.
2. Part B: Subjects will receive Patritumab or placebo with erlotinib. Overall survival
will be the primary outcome. Subjects will need to have EGFR wild-type, locally advance
or metastatic NSCLC and have their cancer progressed after at least one prior systemic
anti-cancer therapy, available recent or archival tumor specimen and may not have had
previous EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy. Only
subjects with high heregulin will be enrolled.
Trial Arms
Name | Type | Description | Interventions |
---|
Placebo + erlotinib | Experimental | Placebo infusion every 3 weeks and oral erlotinib 150 mg/day | |
Patritumab + erlotinib | Experimental | Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day | |
Eligibility Criteria
Inclusion Criteria:
1. Must be greater or equal to 20 years of age
2. Must have cytologically or histologically confirmed NSCLC with either:
- Metastatic disease (Stage IV) OR
- Stage IIIB disease not amenable to surgery or curative intent.
Note: It is permissible to use either AJCC Version 6.0 or the AJCC Version 7.0 staging
system. For sites that use AJCC Version 7.0, T4M0 patients with other ipsilateral
nodules and N0-N2 are still eligible.
3. If tumor histology is adenocarcinoma, must have wild-type EGFR genotype as assessed by
a validated assay that includes exon 19 deletion and exon 21 (L858R) substitution.
4. Must have received one or two prior lines of systemic chemotherapy for advanced or
metastatic disease, one of which must be a platinum-doublet therapy.
5. Must have disease progression or recurrence documented by radiographic assessment
following treatment after last chemotherapy or chemoradiation regimen (completed
within the previous 12 months).
6. Must have available recent (before treatment start) or archival tumor specimen.
7. Must have measurable disease for Part A, measurable disease or non-measurable disease
for Part B
8. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
9. Must have adequate hematological function
10. Must have adequate renal function
11. Must have adequate hepatic function
12. Agreement to use effective contraception while on treatment and for at least 6 months
after end of treatment
13. Must have provided informed consent for study participation.
Exclusion Criteria:
1. Lung adenocarcinoma with an Anaplastic Lymphoma Kinase (ALK) gene rearrangement
2. Left ventricular ejection fraction (LVEF) less than 45%
3. Prior EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy
4. History of other malignancies, except adequately treated non-melanoma skin cancer,
curatively treated in-situ disease, or other solid tumors curatively treated with no
evidence of disease for greater or equal to 5 years
5. History of corneal disease
6. History of interstitial lung disease (ILD)
7. Clinically active brain metastases
8. Uncontrolled hypertension
9. Clinically significant ECG changes
10. Clinically significant (in the opinion of the Investigator) ascites or pleural
effusion requiring chronic medical intervention
11. Myocardial infarction within 1 year before enrollment, symptomatic congestive heart
failure, unstable angina, or unstable cardiac arrhythmia requiring medication
12. Treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or
hormonal therapy within 4 weeks before study drug treatment
13. Therapeutic radiation therapy or major surgery within 4 weeks before study drug
treatment; or palliative radiation within 2 weeks before study drug treatment
14. Participation in clinical drug trials within 4 weeks
15. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known
human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.
16. History of hypersensitivity to any of the study drugs or to any excipients.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 20 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Part A: Progression Free Survival (PFS) in Heregulin-high Participants |
Time Frame: | by trial termination (at 20 months) |
Safety Issue: | |
Description: | PFS is defined as the time from the date of randomization to the earlier of the dates of first objective documentation of radiographic disease progression (as per RECIST Version 1.1 per investigator assessment) or death resulting from any cause.
Kaplan-Meier Estimate. Confidence interval (CI) for median was computed using the Brookmeyer-Crowley method. 80% confidence interval is included in the data table. |
Secondary Outcome Measures
Measure: | Part A: Overall Survival in HRG High Participants |
Time Frame: | by trial termination (at 20 months) |
Safety Issue: | |
Description: | Key secondary efficacy endpoint: Percentage of participants who survived for the length of the trial |
Measure: | Part A: Key Secondary Efficacy Endpoint: Overall Survival in HRG Low Participants |
Time Frame: | by trial termination (at 20 months) |
Safety Issue: | |
Description: | Key secondary efficacy endpoint: Percentage of participants who survived for the length of the trial |
Measure: | Part B: Key Secondary Efficacy Endpoint: PFS, TTD |
Time Frame: | 4 years |
Safety Issue: | |
Description: | PFS is defined as the time from the date of randomization to the earlier of the dates of first objective documentation of radiographic disease progression (TTD, as per RECIST Version 1.1 per investigator assessment) or death resulting from any cause. |
Measure: | Part A: Objective Response Rate (ORR) in HRG High Participants |
Time Frame: | by trial termination (at 20 months) |
Safety Issue: | |
Description: | Key secondary efficacy endpoint: Objective response is defined as percentage of participants achieving complete response (CR) or partial response (PR)
Denominator for percentages is the number of subjects with measurable disease in the full analysis set. The best overall response is the best response [in the order of CR, PR, stable disease (SD), and progressive disease (PD)] among all overall responses recorded from the start of treatment until the subject withdraws from the study. If there is no post-baseline tumor assessment or all post-baseline tumor assessments with overall response being Inevaluable captured in the CRF, the best overall response is classified as Inevaluable. |
Measure: | Part A: Objective Response Rate (ORR) in HRG Low Participants |
Time Frame: | by trial termination (at 20 months) |
Safety Issue: | |
Description: | Key secondary efficacy endpoint: Objective response is defined as percentage of participants achieving complete response or partial response
Denominator for percentages is the number of subjects with measurable disease in the full analysis set. The best overall response is the best response (in the order of CR, PR, SD, and PD) among all overall responses recorded from the start of treatment until the subject withdraws from the study. If there is no post-baseline tumor assessment or all post-baseline tumor assessments with overall response being Inevaluable captured in the CRF, the best overall response is classified as Inevaluable. |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Terminated |
Lead Sponsor: | Daiichi Sankyo, Inc. |
Trial Keywords
- Carcinoma
- Non-Small-Cell Lung
- Lung Neoplasms
- Bronchogenic
- Bronchial Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Erlotinib
- Therapeutic Uses
- Pharmacologic Actions
- Molecular Mechanisms of Pharmacological Action
Last Updated
January 23, 2018